Merck & Company, Inc. (NYSE:MRK) issued an update on its FY17 earnings guidance on Friday morning. The company provided earnings per share guidance of $3.76-3.88 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.85. The company issued revenue guidance of $39.4-40.4 billion, compared to the consensus revenue estimate of $40.05 billion.
Merck & Company, Inc. (NYSE MRK) traded down 0.83% during midday trading on Tuesday, reaching $62.32. The company’s stock had a trading volume of 7,680,067 shares. The firm has a 50-day moving average price of $63.66 and a 200 day moving average price of $63.77. Merck & Company, Inc. has a 52-week low of $58.29 and a 52-week high of $66.80. The stock has a market capitalization of $170.46 billion, a price-to-earnings ratio of 33.74 and a beta of 0.80.
Merck & (NYSE:MRK) last released its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.14. The business had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 25.75%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.93 EPS. Equities research analysts predict that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date is Thursday, September 14th. Merck &’s dividend payout ratio is 76.11%.
A number of equities analysts recently issued reports on MRK shares. Zacks Investment Research upgraded shares of Merck & from a hold rating to a buy rating and set a $72.00 price objective for the company in a research report on Wednesday, May 10th. J P Morgan Chase & Co upped their price target on shares of Merck & from $74.00 to $76.00 and gave the company an overweight rating in a research report on Thursday, May 11th. BMO Capital Markets upped their price target on shares of Merck & from $68.00 to $70.00 and gave the company an outperform rating in a research report on Thursday, May 11th. Vetr raised shares of Merck & from a sell rating to a strong-buy rating and set a $71.50 price objective on the stock in a research note on Monday, May 15th. Finally, BidaskClub lowered shares of Merck & from a hold rating to a sell rating in a research note on Tuesday, July 11th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $69.80.
In other Merck & news, Director C Robert Kidder sold 5,000 shares of Merck & stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $63.54, for a total transaction of $317,700.00. Following the transaction, the director now directly owns 14,317 shares of the company’s stock, valued at $909,702.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.05% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2017/08/08/merck-company-inc-nysemrk-issues-fy17-earnings-guidance-updated.html.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
